Rusan Pharma Limited

About Us

Conceived from the standpoint of professional entrepreneurship, Rusan Pharma Ltd. is a technology driven pharmaceutical company having interests in pharmaceutical research and development, manufacturing and marketing of formulations, APIs and their intermediates. We specialize in the area of opioid de-addiction, critical and acute pain management, anti- tuberculosis, psychotropic drugs and anti- infective.

At Rusan, we are guided by professional leadership and experience, commitment towards quality and delivery, strong understanding of business complexities, exemplary business practices and work ethics and effective implementation.

We are a technology driven Pharmaceutical Company managed by a team of professional technocrats. We specialize in the area of critical pain management, substitution treatment, opioid de-addiction, anti- tuberculosis, psychiatric drugs and anti-infectives.

Our business spectrum includes:

a) Pharmaceutical Research & Development
b) Manufacturing and Marketing of Formulations
c) Synthesis of niche APIs
d) Synthesis of Drug Intermediates
e) Providing contract research and analytical services to our partners
f) Preventing HIV by providing substitution treatment to opiod dependents and injecting drug users

We started our operations in 1994 by manufacturing commercial scale Buprenorphine Hydrochloride. The Indian Process Patent for Buprenorphine Hydrochloride rests with our Chairman, Dr Navin Saxena. Our facilities include an ultra modern formulations unit approved by UK MHRA, South Africa MCC, Zimbabwe MCAZ, WHO-GMP and Sudan MOH.

We market our products in Europe, Middle East, The CIS, South East Asia and The African countries through our own independent offices, distributors and marketing joint ventures.

Some of our products are leaders in their respective therapeutic categories in The CIS and have established themselves as household names.

We have obtained the Certificate of Suitability (COS) of Buprenorphine Hydrochloride from The European Directorate of Quality Medicine (EDQM) and approvals for other products like Fentanyl Citrate, Bisoprolol Fumarate and Tramadol are under way.